Detalles de la búsqueda
1.
Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.
Int J Cancer
; 138(10): 2428-38, 2016 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26685704
2.
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.
Lancet Oncol
; 16(7): 775-86, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26071347
3.
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Lancet
; 384(9961): 2213-27, 2014 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25189358
4.
Management of gonococcal infection among adults and youth: New key recommendations.
Can Fam Physician
; 61(10): 869-73, e451-6, 2015 Oct.
Artículo
en Inglés, Francés
| MEDLINE | ID: mdl-26472793
5.
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.
J Infect Dis
; 210(4): 517-34, 2014 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24610876
6.
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial.
BMC Infect Dis
; 14: 551, 2014 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25927224
7.
Prevalence and correlates of HIV and hepatitis B virus coinfection in Northern Alberta.
Can J Infect Dis Med Microbiol
; 25(1): e8-e13, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24634693
8.
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.
J Infect Dis
; 208(9): 1391-6, 2013 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24092907
9.
Neisseria gonorrhoeae multiantigen sequence typing is beneficial in further characterizing gonococcal populations in Alberta, Canada.
Sex Transm Dis
; 40(9): 744-50, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23945428
10.
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lancet Oncol
; 13(1): 100-10, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22075170
11.
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lancet Oncol
; 13(1): 89-99, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22075171
12.
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial.
Gynecol Oncol
; 127(3): 440-50, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22940493
13.
Prevalence of human papillomavirus infection and associated risk factors in young women in Brazil, Canada, and the United States: a multicenter cross-sectional study.
Int J Gynecol Pathol
; 30(2): 173-84, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21293281
14.
Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines.
Hum Vaccin
; 7(2): 161-9, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21307652
15.
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study.
Hum Vaccin
; 7(12): 1374-86, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22048171
16.
Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada.
Sex Transm Dis
; 36(3): 165-9, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19098690
17.
Retrospective review of tertiary and neurosyphilis cases in Alberta, 1973-2017.
BMJ Open
; 9(6): e025995, 2019 06 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31230001
18.
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
Lancet
; 367(9518): 1247-55, 2006 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16631880
19.
Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.
Expert Rev Vaccines
; 15(3): 367-87, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26902666
20.
Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
Hum Vaccin Immunother
; 12(1): 20-9, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26176261